Northwest Biotherapeutics INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Northwest Biotherapeutics Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical trial efforts, significant operating losses, and substantial doubt regarding its ability to continue as a going concern.
OQB
Northwest Biotherapeutics reported increased net losses and a going concern warning for Q3 2025, while advancing its UK regulatory review and acquiring Advent BioServices.
OQB
Northwest Biotherapeutics reports reduced net losses and improved operating cash flow, while advancing its DCVax-L and DCVax-Direct cancer immunotherapy programs.
OQB
10-Q: Northwest Biotherapeutics Reports Q1 2025 Results, Continues MAA Process and DCVax Development
Northwest Biotherapeutics reports a net loss of $19.3 million for Q1 2025 while advancing its MAA application in the UK and developing its DCVax platform.
OQB
Northwest Biotherapeutics reported a net loss of $19.4 million for the third quarter of 2024, while continuing to advance its regulatory and clinical programs.
OQB
Northwest Biotherapeutics reported a net loss of $36.2 million for the first half of 2024, while advancing its regulatory application and pipeline development.
OQB
Northwest Biotherapeutics reported a net loss of $18.3 million for the first quarter of 2024, while continuing to advance its DCVax platform and pursue regulatory approval in the UK.